FRIDAY, Sept. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has created a "green list" import alert to stop unapproved and unverified glucagon-like peptide 1 (GLP-1) drug ingredients from entering the United States.
GoodRx reports a summer spike in demand for epinephrine auto-injectors as students prepare for school, worsening current shortages.
GoodRx reports that in 2025, novel drug and biosimilar approvals lag slightly behind last year, while first generic approvals are ahead.
GoodRx reveals just how inadequate and restrictive prescription insurance coverage has become.
GoodRx reveals that while most women spend less than $50 a month on menopause-related treatments, cost remains a major barrier, leading some to delay care or forgo treatment altogether.
SaveHealth explores how consumers are leveraging discount card platforms to save money while working with or around their insurance coverage.
TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older.